Viral Hepatitis C Clinical Trial
Official title:
Clinical Relevance of Serum Non-organ-specific Antibodies in Hepatitis C Virus Patients Receiving Direct-acting Antiviral Therapy
The investigators assessed non-organ-specific antibodies before and 24 weeks after the end of therapy with direct-acting antivirals, in order to better clarify the clinical relevance of these antibodies in terms of treatment response and prognostic value. To achieve this goal patients with hepatitis C virus related advanced liver disease, with detectable circulating autoantibodies on at least two determinations before treatment, were enrolled.
About 40-70% of hepatitis C virus patients develop at least an autoimmune extra-hepatic disorder presumably due to the interaction between hepatitis C virus E2 envelope protein and B lymphocyte Cluster of Differentiation-81 receptor. In addition, the same interaction is responsible for the production of different serum non-organ-specific antibodies. The clinical significance of the latter phenomenon has not been fully understood except for the presence of liver kidney microsome-1 antibody, which is linked to a molecular mimicry between the cytochrome enzyme CYP2D6, primarily expressed in the liver, and hepatitis C virus proteins in genetically predisposed subjects. Actually, no data are available about the prevalence and clinical significance of serum non-organ-specific antibodies in hepatitis C virus patients treated with second generation direct-acting antivirals. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04470271 -
Re-linkage to Care of Patients With Hepatitis C
|
||
Completed |
NCT03537196 -
DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C)
|
Phase 4 | |
Recruiting |
NCT05751889 -
Serious Game Interventions to Reduce Viral Hepatitis C Among PLWH-MSM
|
N/A | |
Completed |
NCT04047680 -
eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs
|
||
Not yet recruiting |
NCT04690972 -
"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
|
||
Active, not recruiting |
NCT01953458 -
Therapeutic Option for Hepatitis B and C: a French Cohort
|
||
Completed |
NCT02125500 -
Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection
|
Phase 2 | |
Withdrawn |
NCT01766115 -
Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers
|
Phase 4 |